Cannabidiol is under clinical development by Ananda Scientific and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol is under development for the treatment of schizoprenia, neuropathic pain, opioid replacement and withdrawal, opioid use disorder, Rett syndrome, chronic radiculopathic pain syndromes, post-traumatic stress disorder (PTSD), type 2 diabetes, unspecified cardiovascular disorders, social anxiety disorder and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate was under development for the treatment of inflammatory bowel disease. It is administered through oral route. It acts by targeting CB1 and CB2 receptors. The drug candidate is being developed based on liquid nano-sized delivery technology.
Ananda Scientific overview
Ananda Scientific improves health and the quality of life with oral, non-psychoactive products based on cannabis plant chemistry. The company is headquartered in Arapahoe, Colorado, the US
For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.